Study Enrollment

Your details will not be published or shared.

Clinical Trial

A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls

The purpose of this study is to evaluate the safety and tolerability of the investigational drug, TAK-071, in subjects with Parkinsons disease (PD).

Eligibility Criteria

  • Has been diagnosis Parkinsons Disease PD Patient is 40 to 65 years old

Contact Information

    Dedi McLane

    (706) 721-2798